Your session is about to expire
← Back to Search
OTX-TKI for Age-Related Macular Degeneration
Study Summary
This trial will test a new medicine for age-related macular degeneration. Researchers will study how well the medicine works and if it is safe.
- Age-Related Macular Degeneration (AMD)
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many healthcare facilities are participating in this research trial?
"This study is presently enrolling patients at 14 different sites, including Site 6 in Bakersfield, California; Site 3 in Altamonte Springs, Florida; and Site 5 in Oxnard, Texas."
What medical conditions are Aflibercept treatments frequently employed to address?
"Aflibercept is a viable treatment option for patients suffering from the degenerative wet age-related macular edema, as well as those with diabetes induced macular swelling."
What are the potential hazards associated with Aflibercept treatment?
"Due to its early-stage testing, aflibercept's safety has been given an assessment of 1 on our scale. This is because Phase I trials provide limited data regarding the efficacy and security of this medication."
What is the prime aim of this research?
"According to the research institute, Ocular Therapeutix, Inc., primary outcomes measured over a course of 12 months will be changes in Best Corrected Visual Acuity (BCVA). Secondary results being evaluated include BCVA change from baseline, prevalence of foveal fluid absence and proportion of patients requiring rescue therapy."
Are there any precedents of research that have utilized Aflibercept?
"The pharmaceutical aflibercept was initially trialed in 2014 at M.D Anderson Cancer Center, and there have been 231 trials conducted since then. As of now, 45 studies that are recruiting participants can be found primarily within Bakersfield, California."
What is the enrollment cap for this clinical investigation?
"At present, this medical trial is not recruiting. It first appeared on July 28th 2021 and was recently updated on September 1st 2022. Nonetheless, there are 159 other experiments actively enrolling individuals with macular degeneration and 45 trials that accept Aflibercept patients."
Is there currently a call for enrollment in this experiment?
"Unfortunately, this investigation is not accepting new participants at the present moment. The clinical trial was first listed on July 28th 2021 and last updated September 1st 2022. However, there are 159 trials for macular degeneration and 45 studies for Aflibercept that are actively searching for patients to join their program."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger